ERBB2 and serous adenocarcinoma: Regarding targeted therapy, for patients with human epidermal growth factor receptor 2 (HER2)-positive serous carcinomas, trastuzumab in combination with paclitaxel/carboplatin enhanced progression-free survival as a first- to fourth-line therapy in a phase II trial [26].